TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Self-confidence for problem solving
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Self-confidence for clinical judgment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Self-confidence for clinical decision-making
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of new pathological fractures
Endpoint domain: Adverse events/effects
Primary endpoint: Mean total area under the serum concentration‐time curve of simvastatin and simvastatin acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean peak concentrations of simvastatin and simvastatin acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half‐life of simvastatin acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Raynaud's condition score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liking of cannabis-associated stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Demand for cannabis puffs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in ALT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Reduction in AST levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: SLAM-R improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BILAG improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance efficiency of subglottic secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ApoC‐III levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LpB:C:E levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sum of ApoC‐III‐containing lipoproteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cell proliferation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of PRA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of ER-alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference in change in pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Requirement for rescue morphine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: IgE antibodies to purified ω‐5 gliadin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnostic specificity of ω‐5 gliadin ELISA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value of ω‐5 gliadin ELISA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: correlation dimension in CAD patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SPTs efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of moderate or greater TR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PBAC score in the non-menorrhagic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amenorrhea development
Endpoint domain: Adverse events/effects
Primary endpoint: pain related behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of exclusive breast-feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of joint crack sound on the ipsilateral side to head rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FFI score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: CVD events/deaths
Endpoint domain: Mortality/survival
Primary endpoint: Improvement on K-SADS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 30-day Glasgow Outcome Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in the number of antiglaucoma medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative success rate
Endpoint domain: Mortality/survival
Primary endpoint: Vision-related quality of life (VFQ score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: clinical success rate at day 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical cure rate at day 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean time without recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of atherosclerotic plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Psychotic Depression Assessment Scale (PDAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of botulinum toxins for hyperfunctional facial lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crow's feet severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of wound healing disorders necessitating antibiotic treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Aggregate STI prevalence
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of stimulant treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety profile of stimulant treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Median episode length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with prevented lesion development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Irritability symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma dehydrocholesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: coalition development
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: conflict resolution
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: leadership satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: tolerability of tirilazad
Endpoint domain: Adverse events/effects
Primary endpoint: Ratio of supporting phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic alanine aminotransferase concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Hepatic aspartate aminotransferase concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Hepatic steatosis index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Rate of false-positive results for T. trichiura
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of false-positive results for A. lumbricoides
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of false-negative results for T. trichiura
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of false-negative results for A. lumbricoides
Endpoint domain: Adverse events/effects
Primary endpoint: Response to tretinoin plus treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of IOP > 25 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Frequency of IOP > 30 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Need for opiate injections
Endpoint domain: Adverse events/effects
Primary endpoint: time to full feeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in intensity of cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-rater agreement for myocardial ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: vascular permeability index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leukocyte nadir counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: KW gain around implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total shrinkage of KW
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hunger scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Abstinence rate at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TEWL (Trans Epidermal Water Loss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Age of introduction of solids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exclusive breastfeeding rate at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight at 6 weeks of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Request for additional pain medication
Endpoint domain: Adverse events/effects
Primary endpoint: maximum response amplitude of pupillary dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone loss (BL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Roughness average (Ra) of denture liners
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 h weighted mean serum cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Initial memory strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subsequent decay of memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decrease in leptin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean decrease in adiponectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean decrease in resistin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: sleep onset
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Cytokine expression changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: discounted life year gained
Endpoint domain: Mortality/survival
Primary endpoint: Event reduction
Endpoint domain: Mortality/survival
Primary endpoint: FAAM score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of injections
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rhinitis score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of daily antihistamines use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal resistance measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: CT ratio of liver-spleen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of akinesia and analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall survival rate after 3 years
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistence of brightly reflective particles in the corneal interface layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spirometric parameters improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Radiographic findings improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores after ESE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of VAS scores of 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic cure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total adiposity increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visceral adiposity increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diminished DI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Degree of liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ALT activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Scores of symptoms of hypochondriac pain and dry mouth
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cerebral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Serum 17beta-estradiol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Eradication of H pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Relapse after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvements in affective symptoms of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum 25OHD levels reaching the target of 75 nmol/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved clearance of bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in the rate of exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PVR volume decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low back pain improvement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Solid arthrodesis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Erosive wear of enamel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort of appliance use
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bone density in the buccal region of the graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in PTSD symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in depression and distressed mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postherpetic neuralgia (PHN) development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Acute pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isovolumic relaxation period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: high-density lipoprotein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma calcium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma phosphate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fully successful outcome defined as not requiring repeat antimicrobial therapy or amputation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maxillary molar anchorage loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: blood folate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reinfection-adjusted cure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Bone mineralization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete remission (HAM-D score ≤ 7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response (HAM-D score reduction ≥ 50%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: renal scarring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 30-month overall survival (OS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Mortality rate ratio (MRR)
Endpoint domain: Mortality/survival
Primary endpoint: Diastolic blood pressure rise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of fungal infections requiring therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Composite endpoint of cardiac death and MI
Endpoint domain: Mortality/survival
Primary endpoint: Preservation of sinus rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reablation rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Fecal continence score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clot weight reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: depressive symptom levels at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SGZ scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Bracket failure rates
Endpoint domain: Mortality/survival
Primary endpoint: Mean times to first failure
Endpoint domain: Mortality/survival
Primary endpoint: Adhesive removal times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: mean tidal volume (Vt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AVVQ score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment enrollment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Median reduction in PDAI total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alleviation of short-term adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Alleviation of abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in CNS-LS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall quality of life (QOL) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall quality of relationships (QOR) scores
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Flexibility (length of Sit and Reach)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance ability (open eyes perimeter)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance ability (closed eyes perimeter)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time of closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: hematuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: serum IgA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Duration of the encounter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of diagnoses discussed per visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with the encounter
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of improvement as indicated by Oswestry questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Plasma levels of Factor II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma levels of Factor V
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma levels of vWF:Ag
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Visit satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Working alliance with psychiatrist
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Use of antidepressants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on Modified Prosocial subscale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Mean frequency and duration of attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of patients with severe headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes